Uremic neuropathy is peripheral nerve injury that develops in the setting of advanced kidney disease, and its most important feature is how often it is present before it is obvious. In a Tunisian cohort study of 31 children with stage G5 chronic kidney disease, uremic neuropathy was diagnosed in 45% of participants using nerve conduction testing, including 13% who had silent neuropathy with no symptoms.3 Among adults, the same gap appears: in 200 patients with predialysis CKD studied in India, prevalence was 45% based on clinical symptoms and 90% on electrophysiological testing.1
That gap between what patients feel and what testing finds is the practical argument for looking early rather than waiting for symptoms to become convincing.
Key takeaways
- Symptoms lag behind nerve dysfunction. Silent neuropathy is well documented in advanced CKD.3
- Severity tracks with kidney function. Prevalence rose from 55% in Stage 3 to 84.8% in Stage 5 in one adult cohort.2
- Uremia is a driver, not the only driver. Nutritional, medication-related, autoimmune and structural contributors can overlap.
- Testing separates fiber types. Electrodiagnostic testing is performed on site and distinguishes large-fiber patterns from what small fibers are doing.
- No regeneration or cure is promised. The goals are reduced ongoing injury, better function and safer walking.
What uremic neuropathy is
Uremic neuropathy describes peripheral nerve injury occurring alongside advanced kidney dysfunction. Patients describe burning, numbness, electric-shock sensations or reduced feeling, usually starting in the feet and usually on both sides.
Those descriptions do not by themselves identify which nerve fibers are involved or what is driving the injury. In the Tunisian pediatric cohort, axonal neuropathy was the predominant pattern and no demyelinating cases were identified.3
Small fiber and large fiber involvement look different
Small fiber involvement tends to produce burning, hot-coal sensations and pain at night. Large fiber involvement tends toward numbness, reduced vibration sense and altered protective sensation, which is what affects balance and gait safety.
The distinction matters because it changes what is being monitored and what counts as a meaningful change over time.
Why the driver search continues even when CKD is obvious
When kidney disease is advanced, it is easy to stop the diagnostic search there. But a nerve can be under pressure from several directions at once, and the contributors that can actually be reduced are often not the kidney disease itself.
The overlaps that most often matter
- Diabetes. Many patients with CKD also have diabetes, and diabetic nerve injury can intensify or mimic uremic nerve injury.
- Nutritional deficiency. Diet restriction, absorption problems and medication effects all raise the risk in this population.
- Medications. The medication list deserves as much attention as the kidney stage.
- Toxic and environmental exposures, including alcohol.
- Autoimmune processes and structural compression, which can add a second, separate failure point.
Identifying which of these is contributing is what turns a diagnosis into a plan. Our overview of the hidden drivers of peripheral neuropathy covers the ones most often left unexamined.
How the evaluation works at Regenerve
The evaluation answers two separate questions: which nerves are affected, and what is affecting them. Testing addresses the first. History, examination and metabolic review address the second.
What it includes
- Electrodiagnostic testing (EMG and nerve conduction studies), performed on site
- Metabolic and nutritional review, aimed at contributors that can be corrected
- VNG balance testing where balance is affected. VNG is a diagnostic test of inner-ear balance function, not a treatment.
What testing does not settle
A nerve conduction study describes the injury. It does not name the cause, and a study that reads close to normal does not rule out small fiber involvement. That is why the result is interpreted alongside the rest of the evaluation rather than on its own.
Treatment, and what it is aimed at
Surgery is not part of the treatment plan for uremic neuropathy. Care is focused on evaluation, diagnostic mapping and non-surgical treatment aimed at reducing ongoing nerve injury and supporting function.
The therapies used
- Class 4 photobiomodulation and class 3B cold laser, selected when the symptom pattern and evaluation support them
- Whole-body infrared, used as part of the overall plan
- Metabolic and nutritional care, where a correctable contributor has been identified
Kidney disease adds a constraint that has to be respected throughout: nutritional and metabolic changes in this population are made in coordination with the nephrology team, not independently of it.
Orthobiologic injections
Orthobiologic injections (PRP and BMAC) are offered in selected situations.
What we do not promise
We do not promise nerve regeneration, reversal or a cure. Where nerve injury has accumulated over years of advanced kidney disease, the honest goals are reduced ongoing injury, better day-to-day function and safer walking.
Qutenza in this setting
Qutenza (capsaicin 8% patch) is indicated in adults for neuropathic pain associated with postherpetic neuralgia and for neuropathic pain associated with diabetic peripheral neuropathy of the feet.4 Uremic neuropathy is not an approved indication, so any use here is off-label and must be described that way in the plan.
Where it is used, it is applied in clinic by a clinician, never dispensed for home use, and repeated no more often than every three months. More detail is on our page about the Qutenza capsaicin 8% patch.
Practical steps while you are being evaluated
- Inspect both feet daily if sensation is reduced, using a mirror for the soles.
- Check for skin breakdown, calluses and pressure areas, and act on them early.
- Bring a current, complete medication list to every appointment.
- Report new weakness, new falls or a rapidly progressing change promptly rather than at the next scheduled visit.
Regenerve in the St. Louis region
Regenerve treats peripheral neuropathy for patients across the St. Louis region, Missouri and Illinois, including Edwardsville, Glen Carbon, Collinsville, Troy and Maryville. The clinic is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport. Call or text (314) 886-5902, or email info@regenerve.com.
Your next step
If you have kidney disease and nerve symptoms, the free five-question Nerve Damage Score identifies which driver category most likely applies to you, and your answers guide what we evaluate first.
Frequently asked questions
How often does neuropathy occur in chronic kidney disease?
It depends heavily on whether you count symptoms or nerve testing. Among 200 adults with predialysis CKD in one Indian hospital study, prevalence was 45% based on clinical symptoms and 90% on electrophysiological testing.1 Part of that gap is small-fiber injury that routine testing under-reports; see small fiber neuropathy symptoms and testing.
Does it get worse as kidney function declines?
That is the pattern reported. In a cross-sectional study of 105 adults with CKD in Amritsar, neuropathy prevalence rose from 55% in Stage 3 to 84.8% in Stage 5.2 Our evaluation, including on-site electrodiagnostic testing, is described on the neuropathy services page.
Why do my feet burn at night if the problem is my kidneys?
Burning at night usually points toward small-fiber involvement, and small fibers can be affected while routine nerve conduction testing still looks close to normal. See burning feet and nerve pain.
Could something other than my kidney disease be causing this?
Often, yes. Nutritional deficiency is one of the most common overlapping contributors in this group, and it is correctable when it is found. See functional B12 deficiency and neuropathy.
Sources
- Jasti DB, Mallipeddi S, Apparao A, Vengamma B, Sivakumar V, Kolli S, “A Clinical and Electrophysiological Study of Peripheral Neuropathies in Predialysis Chronic Kidney Disease Patients and Relation of Severity of Peripheral Neuropathy with Degree of Renal Failure,” Journal of Neurosciences in Rural Practice, 2017;8(4):516-524, doi:10.4103/jnrp.jnrp_186_17, https://ruralneuropractice.com/a-clinical-and-electrophysiological-study-of-peripheral-neuropathies-in-predialysis-chronic-kidney-disease-patients-and-relation-of-severity-of-peripheral-neuropathy-with-degree-of-renal-failure/
- Singh P, et al., “Electrophysiological Characterization and Stage-Dependent Progression of Uremic Neuropathy in Chronic Kidney Disease,” Annals of Medicine and Medical Sciences, published May 21, 2026, Vol. 05 (2026), pages 707-711, https://ammspub.com/index.php/amms/article/view/579
- Yahyaoui A, Gammoudi N, Nouir S, Mabrouk S, Ghali H, Abroug S, Sakly G, “Prevalence of uremic neuropathy and the effect of dialysis in children with end-stage renal disease: A cohort study,” PLOS One, November 25, 2025, doi:10.1371/journal.pone.0337696, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0337696
- U.S. Food and Drug Administration, “QUTENZA (capsaicin) 8% topical system — prescribing information,” label effective July 7, 2026, via DailyMed, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad93-4f15-bb38-5da76a71c735